
Zynex Inc (ZYXI) Stock Forecast & Price Target
Zynex Inc (ZYXI) Analyst Ratings
Bulls say
Zynex Inc. reported a 16% year-over-year increase in orders for fiscal year 2024, indicating strong demand for its electrotherapy and pain management medical devices. The company's effective management strategies aim to increase revenue per sales representative to $1 million, further enhancing its financial performance. Additionally, the results from recent clinical studies and the planned expense reduction expected to yield approximately $35 million in annual savings contribute to a positive outlook for Zynex's growth potential and market position.
Bears say
Zynex Inc. is facing significant challenges, as the company has indicated a substantial decline in its expected Q1 2025 sales, projecting at least $30 million, which reflects a 37% year-over-year decrease. Additionally, the fourth-quarter revenue figures showed a 3% year-over-year decline to $46 million, which was notably below expectations, coupled with the trend of decreasing Device sales by 9% year-over-year. The financial outlook for 2025 has been revised downwards significantly to an estimated $140 million, indicating a 28% year-over-year decline, compounded by concerns over operational visibility, competitive pressures, and regulatory hurdles.
This aggregate rating is based on analysts' research of Zynex Inc and is not a guaranteed prediction by Public.com or investment advice.
Zynex Inc (ZYXI) Analyst Forecast & Price Prediction
Start investing in Zynex Inc (ZYXI)
Order type
Buy in
Order amount
Est. shares
0 shares